SUMOylation alterations are associated with multidrug resistance in hepatocellular carcinoma

Molecular Medicine Reports

Volumn 9, Issue 3, 2014, Pages 877-881

  Qin, Yu ^a,b   Bao, Huijing ^a   Pan, Yi ^a   Yin, Meilin ^a   Liu, Yunde ^a   Wu, Shangwei ^a   Li, Huikai ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Hepatocellular carcinoma; Multidrug resistance; Sentrin specific protease 1; SUMOylation; Ubiquitin like modifier activating enzyme 2

Indexed keywords

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG RESISTANCE, NEOPLASM; ENDOPEPTIDASES; FLUOROURACIL; HEP G2 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; SUMO-1 PROTEIN; SUMOYLATION; UBIQUITIN-ACTIVATING ENZYMES; UP-REGULATION;

EID: 84893836452     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.1882     Document Type: Article

References (30)

1. Geiss-Friedlander R and Melchior F: Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol 8: 947-956, 2007.
2. Meluh PB and Koshland D: Evidence that the MIF2 gene of Saccharomyces cerevisiae encodes a centromere protein with homology to the mammalian centromere protein CENP-C. Mol Biol Cell 6: 793-807, 1995.
3. Shen Z, Pardington-Purtymun PE, Comeaux JC, Moyzis RK and Chen DJ: UBL1, a human ubiquitin-like protein associating with human RAD51/RAD52 proteins. Genomics 36: 271-279, 1996.
4. Okura T, Gong L, Kamitani T, Wada T, Okura I, Wei CF, Chang HM and Yeh ET: Protection against Fas/APO-1-and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J Immunol 157: 4277-4281, 1996.
5. Seeler JS and Dejean A: Nuclear and unclear functions of SUMO. Nat Rev Mol Cell Biol 4: 690-699, 2003.
6. Wadosky KM and Willis MS: The story so far: post-translational regulation of peroxisome proliferator-activated receptors by ubiquitination and SUMOylation. Am J Physiol Heart Circ Physiol 302: H515-H526, 2012.
7. Gong L, Li B, Millas S and Yeh ET: Molecular cloning and characterization of human AOS1 and UBA2, components of the sentrin-activating enzyme complex. FEBS Lett 448: 185-189, 1999.
8. Muller S, Berger M, Lehembre F, Seeler JS, Haupt Y and Dejean A: c-Jun and p53 activity is modulated by SUMO-1 modification. J Biol Chem 275: 13321-13329, 2000.
9. Liu G and Warbrick E: The p66 and p12 subunits of DNA polymerase delta are modified by ubiquitin and ubiquitin-like proteins. Biochem Biophys Res Commun 349: 360-366, 2006.
10. Tanaka K, Nishide J, Okazaki K, Kato H, Niwa O, Nakagawa T, Matsuda H, Kawamukai M and Murakami Y: Characterization of a fission yeast SUMO-1 homologue, pmt3p, required for multiple nuclear events, including the control of telomere length and chromosome segregation. Mol Cell Biol 19: 8660-8672, 1999.
11. Bachant J, Alcasabas A, Blat Y, Kleckner N and Elledge SJ: The SUMO-1 isopeptidase Smt4 is linked to centromeric cohesion through SUMO-1 modification of DNA topoisomerase II. Mol Cell 9: 1169-1182, 2002.
12. Azuma Y, Arnaoutov A and Dasso M: SUMO-2/3 regulates topoisomerase II in mitosis. J Cell Biol 163: 477-487, 2003.
13. Wu N, Kong X, Ji Z, Zeng W, Potts PR, Yokomori K and Yu H: Scc1 sumoylation by Mms21 promotes sister chromatid recombination through counteracting Wapl. Genes Dev 26: 1473-1485, 2012.
14. McAleenan A, Cordon-Preciado V, Clemente-Blanco A, Liu IC, Sen N, Leonard J, Jarmuz A and Aragón L: SUMOylation of the α-kleisin subunit of cohesin is required for DNA damage-induced cohesion. Curr Biol 22: 1564-1575, 2012.
15. Luo K, Zhang H, Wang L, Yuan J and Lou Z: Sumoylation of MDC1 is important for proper DNA damage response. EMBO J 31: 3008-3019, 2012.
16. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA, et al: Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 44: 239-245, 2010.
17. Correia AL and Bissell MJ: The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat 15: 39-49, 2012.
18. Doublier S, Belisario DC, Polimeni M, Annaratone L, Riganti C, Allia E, Ghigo D, Bosia A and Sapino A: HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer 12: 4, 2012.
19. Brökers N, Le-Huu S, Vogel S, Hagos Y, Katschinski DM and Kleinschmidt M: Increased chemoresistance induced by inhibition of HIF-prolyl-hydroxylase domain enzymes. Cancer Sci 101: 129-136, 2010.
20. Fabregat I, Roncero C and Fernández M: Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int 27: 155-162, 2007.
21. Homann N, Pauligk C, Luley K, et al: Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer 130: 1706-1713, 2012.
22. Kitagawa K, Kawada K, Morita S, et al: Prospective evaluation of corrected QT intervals and arrhythmias after exposure to epirubicin, cyclophosphamide, and 5-fluorouracil in women with breast cancer. Ann Oncol 23: 743-747, 2012.
23. Nagai S, Davoodi N and Gasser SM: Nuclear organization in genome stability: SUMO connections. Cell Res 21: 474-485, 2011.
24. Cai Q and Robertson ES: Ubiquitin/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization. PLoS One 5: e12636, 2010.
25. Ding B, Sun Y and Huang J: Overexpression of SKI oncoprotein leads to p53 degradation through regulation of MDM2 protein sumoylation. J Biol Chem 287: 14621-14630, 2012.
26. Bettermann K, Benesch M, Weis S and Haybaeck J: SUMOylation in carcinogenesis. Cancer Lett 316: 113-125, 2012.
27. Guo WH, Yuan LH, Xiao ZH, Liu D and Zhang JX: Overexpression of SUMO-1 in hepatocellular carcinoma: a latent target for diagnosis and therapy of hepatoma. J Cancer Res Clin Oncol 137: 533-541, 2011.
28. Kessler JD, Kahle KT, Sun T, et al: A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335: 348-353, 2012.
29. Wang Q, Xia N, Li T, et al: SUMO-specific protease 1 promotes prostate cancer progression and metastasis. Oncogene 32: 2493-2498, 2013.
30. Wartenberg M, Ling FC, Muschen M, et al: Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J 17: 503-505, 2003.